Anticoagulant therapy control in primary healthcare setting
摘要
The aim of the study was to evaluate efficiency anticoagulant therapy control in primary healthcare setting. The prospective, controlled study involved 301 patients with «non-valvular» atrial fibrillation, receiving various anticoagulant drugs in 2013–2015. After discharge the patients were advised to visit anticoagulant therapy control department. The risk of thromboembolic complications and the risk of bleeding were assessed with CHA2DS2VASc scale HAS-BLED, respectively. Major bleeding was assessed with TIMI scale. The time in therapeutic range for Warfarin was assessed for the patient taking warfarin. The study involved 301 patients with non-valvular atrial fibrillation taking anticoagulants: warfarin – 49 (16%), rivaroxaban – 34 (11%), apixaban – 81 (28%) and dabigatran –137 (45%). Minor bleeding was found in all groups. Large bleeding was found in patients receiving warfarin, dabigatran and rivaroxaban.
关于作者
Z. Salpagarova
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
D. Andreev
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
D. Sichev
Russian Medical Academy of Post-Graduate Education
俄罗斯联邦
俄罗斯联邦
A. Bikova
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
S. Syrkin
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
S. Suchkova
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
参考
1. Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012; 379: 1835–1846.
2. Mani H., Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des. Devel. Ther. 2014; 8: 789–798.
3. Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008; 12 (6): 160–198.
4. Wan Y., Heneghan C., Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ. Cardiovasc Qual Outcomes. 12 (2): 84–91.
5. Calvo Romero J.M., Lima Rodriguez E.M. New oral anticoagulants in the treatment of venous thromboembolic disease. Semergen. 2013; 39 (3): 146–149.
6. Healey J.S., Eikelboom J., Douketis J. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012; 126 (3): 343–348.
评论
浏览:
263
Email this article 